LONGBIO-B Proposes Implementation of H Share Option and Incentive Schemes

The board of LONGBIO-B (01779) has resolved to propose the adoption of an H share option scheme and an H share incentive scheme for the company.

The proposed schemes aim to establish and improve the company's long-term incentive mechanisms, attract and retain core talent to drive business growth, and align the interests of shareholders, the company, and its employees.

They are part of a multi-faceted strategy covering research and development, clinical development, and commercialization, intended to advance the company's commercial transformation and enhance its value.

The plans also seek to foster collaboration for a future of shared creation and benefits, while driving the achievement of the company's long-term strategic and performance goals.

The schemes are expected to provide the company with flexible tools to retain, reward, compensate, and/or incentivize eligible individuals.

The H shares to satisfy options granted under the H share option scheme will be sourced via: (i) the issue and allotment of new H shares; and/or (ii) the transfer of the company's treasury shares, if any.

The H shares involved in awards granted under the H share incentive plan are to be those acquired by a designated trustee through: (i) purchasing new H shares from the company at par value; (ii) utilizing scheme funds to purchase on the secondary market at prevailing prices; and/or (iii) using the company's treasury shares, if any.

The maximum number of H shares that may be allotted and issued or transferred from treasury to satisfy all options and awards under these proposed schemes, plus any under the company's other share plans, shall not exceed 10% of the total issued shares of the company (excluding any treasury shares) on the date shareholders approve the scheme limit.